Company intelligence / Profile preview

Fuzionaire Theranostics

The Woodlands, Texas, United Statesfuzionairetx.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Fuzionaire Theranostics has presented initial preclinical data for its GRPR-targeting prostate cancer program. The company’s pipeline includes discovery-stage programs in lung cancer and PSMA/GRPR-positive prostate cancer. No active clinical trials are currently listed on ClinicalTrials.gov as of May 2025.

Therapeutic areas: Oncology
Modalities: Radiopharmaceuticals (including PET diagnostics and radioligand therapies)peptide-based theranostics
Industry: Biotech

Drug pipeline

5 assets

18F/tba theranostic pair

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with academic institutions such as McGill University; seeking new partners to expand use of HetSiFA technology.

Beyond the preview

Go deeper on Fuzionaire Theranostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzionaire Theranostics.

Explore the full profile